Aptevo Therapeutics Inc. (APVO) vs Virax Biolabs Group Limited (VRAX)

Aptevo Therapeutics Inc. and Virax Biolabs Group Limited are both Biotechnology companies. Aptevo Therapeutics Inc. and Virax Biolabs Group Limited are of similar size ($3.4M and $3.3M). Virax Biolabs Group Limited has negative trailing earnings, so its P/E is not meaningful; Aptevo Therapeutics Inc. trades at 0.0×. Across the 9 metrics below, Aptevo Therapeutics Inc. leads on 5 and Virax Biolabs Group Limited on 4.

Valuation

Metric APVO VRAX Biotechnology median
P/E 0.00 n/m 7.88
P/S 0.17 n/m 11.47
P/B 0.37 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.86 0.74
EV/Sales 0.00 n/m 10.73
Earnings yield 86,377.14% (222.08%) (28.84%)
Free cash flow yield (1,127.28%) 0.00% (23.03%)

Profitability

Metric APVO VRAX Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (446.89%) 0.00% (57.72%)
Return on assets (186.29%) 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric APVO VRAX Biotechnology median
Revenue growth (TTM) 92.94% — 5.64%
EPS growth (last fiscal year) 99.72% 68.79% —
Revenue growth, 5-year CAGR (26.64%) (36.88%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric APVO VRAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.08 9.97 4.73
Net debt to EBITDA 0.83 1.08 0.96

Dividend

Metric APVO VRAX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric APVO VRAX Biotechnology median
Market cap 3.43m 3.28m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack